By highlighting the therapeutic potential in the HER2-low subgroup, DESTINY-Breast04 has expanded the treatment landscape for breast cancer and underscored the importance of redefining HER2 status in clinical practice. This evidence concerns the gene ERBB2 and breast cancer.